Cross-national drug price comparisons with economic weights in external reference pricing in Germany

References

• Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–185.
   PubMed Web of Science ®Google Scholar
• Danzon PM. Price Discrimination for pharmaceuticals: welfare effects in the US and the EU. Int J Econ Business. 1997;4(3):301–322.
   Google Scholar
• Danzon P, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3(3):183–205.
   PubMedGoogle Scholar
• Neubauer G, Morasch K, Gmeiner A Opportunities and benefits of price differentiation for innovative medicines. Study for the Association of Research-based Pharmaceutical Companies e.V. (VFA) 2013.
   Google Scholar
• Scherer FM, Watal J. Post‐TRIPS options for access to patented medicines in developing nations. J Int Econ Law. 2002;5(4):913–939.
   Web of Science ®Google Scholar
• Ramsey FP. A Contribution to the Theory of Taxation. Econ J. 1927;37(145):47–60.
   Google Scholar
• Kanavos P, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Economics Policy and Law. 2011;6(3):337–367.
   PubMed Web of Science ®Google Scholar
• NASHI [National Association of Statutory Health Insurance Funds]. AMNOG- Evaluation of new pharmaceutical. Berlin 2016. [cited 2016 Dec 11]. Available from: https://www.gkv-spitzenverband.de/english/statutory_health_insurance/amnog_evaluation_of_new_pharmaceutical/amnog_english.jspspitzenverband.de/krankenversicherung/krankenversicherung_grundprinzipien/alle_gesetzlichen_krankenkassen/alle_gesetzlichen_krankenkassen.jsp#lightbox (accessed on: 02/ 02/2016).
   Google Scholar
• Gerber A, Stock S, Dintsios C-M. Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing? Pharmacoeconomics. 2011;29(7):549–554.
   PubMed Web of Science ®Google Scholar
• Carone G, Schwierz C, Xavier A Cost-containment policies in public pharmaceutical spending in the EU. European Commission - Directorate-General for Economic and Financial Affairs 2012; Economic Papers No 461.
   Google Scholar
• Brekke KR, Grasdal AL, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation? Eur Econ Rev. 2009;53(2):170–185.
   Web of Science ®Google Scholar
• Kaiser U, Mendez SJ, Rønde T, et al. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark. J Health Econ. 2014;36:174–187.
   PubMed Web of Science ®Google Scholar
• Maini L, Pammolli F Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market. mimeo, 2017, Available from: https://scholar.harvard.edu/files/lucamaini/files/reference_pricing_as_a_deterrent_to_entry.pdf.
   Google Scholar
• Rovira J. Are national drug expenditure control policies compatible with a single European market? Pharmacoeconomics. 1996;10(2):4–13.
   PubMed Web of Science ®Google Scholar
• Towse A. The pros and cons of a single Euro price for drugs. Pharmacoeconomics. 1998;13(3):271–276.
   PubMed Web of Science ®Google Scholar
• Chalkidou K, Anderson G, Faden R. Eliminating drug price differentials across government programmes in the USA. Health Economics Policy and Law. 2011;6(1):43–64.
   PubMed Web of Science ®Google Scholar
• Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2013;22(12):1405–1514.
   PubMed Web of Science ®Google Scholar
• European Commission. GDP and beyond. Measuring progress in a changing world, communication from the commission to the council and the European Parliament. COM 2009; No 433, Brussels.
   Google Scholar
• Hitiris T, Posnett J. The determinants and effects of health expenditure in developed countries. J Health Econ. 1992;11(2):173–181.
   PubMed Web of Science ®Google Scholar
• Moscone F, Tosetti E. Health expenditure and income in the United States. Health Econ. 2010;19(12):1385–1403.
   PubMed Web of Science ®Google Scholar
• Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand J Econ. 2002;33(3):469–487.
   PubMed Web of Science ®Google Scholar
• Culyer AJ. The NHS and the market. In: McLachlan G, Maynard A, editors. The public/private mix for health: the relevance and effects of change. London: Nuffield Provincial Hospitals Trust; 1982.
   Google Scholar
• OECD. A disease-based comparison of health systems: what is best and at what costs? Paris: OECD Publishing; 2003.
   Google Scholar
• Parkin D, McGuire A, Yule B. Aggregate health care expenditures and national income: is health care a luxury good? J Health Econ. 1987;6(2):109–127.
   PubMed Web of Science ®Google Scholar
• Espin J, Rovira J, de Labry AO. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 1: External Reference Pricing. WHO/HAI 2011. 1–50.
   Google Scholar
• Burg F. Calculation of purchasing power parities. Econ Stat. 2011;8:793–801.
   Google Scholar
• Eurostat. Eurostat-OECD methodological manual on purchasing power parities. Paris: OECD Publishing; 2012.
   Google Scholar
• Cassel D, Ulrich V Manufacturers delivery prices in the European pharmaceutical markets as reimbursement framework in the GKV pharmaceutical supply. On the problem of the concept of external reference prices. Expert opinion for the VFA 2012, Berlin. [cited 2014 Feb 02]. Available online: www.vfa.de/…/herstellerabgabepreise-auf-europaeischen-arzneimittelmaerkten.pdf.
   Google Scholar
• Taylor AM, Taylor MP. The purchasing power parity debate. J Econ Perspect. 2004;18(4):135–158.
   Web of Science ®Google Scholar
• Égert B Real convergence, price level convergence and inflation differentials in Europe. CESifo Working Paper 2007; No. 2127.
   Google Scholar
• Krugman P. Pricing to market when the exchange rate changes. In: Arndt SW, Richardson JD, editors. Real-financial linkages among open economies. Cambridge, MA: MIT Press; 1987; 49 - 70.
   Google Scholar
• Rogoff K. The purchasing power parity puzzle. J Econ Lit. 1996;34(2):647–668.
   Web of Science ®Google Scholar
• Jaumotte F, Morsy H Determinants of inflation in the Euro Area: the role of labor and product market institutions. IMF Working Paper 2012; 12/37.
   Google Scholar
• Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–1285.
   PubMed Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171.
   PubMed Web of Science ®Google Scholar
• Eurostat. Database. 2012; [cited 2018 Jan 11]. Available from: http://ec.europa.eu/eurostat/de/data/database.
   Google Scholar
• Schiedsstelle [Arbitration Board]. Arbitration Agreement Sativex (Cannabis Sativa). Berlin; 2013.
   Google Scholar
• Hall R, Jones C. The value of life and the rise in health spending. Q J Econ. 2007;122:39–72.
   Web of Science ®Google Scholar
• Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet. 2013;373(9659):240–249.
   Web of Science ®Google Scholar
• Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–2654.
   PubMed Web of Science ®Google Scholar
• Vogler S, Zimmermann N, Babar Z. Price comparison of high-cost originator medicines in European countries. Expert Rev Pharmacoecon Outcomes Res. 2017;17:221–230.
   PubMed Web of Science ®Google Scholar
• Malueg DA, Schwartz M. Parallel imports, demand dispersion, and international price discrimination. J Int Econ. 1994;37(3–4):167–195.
   Web of Science ®Google Scholar
• Towse A, Pistollato M, Mestre-Ferrandiz J, et al. European Union pharmaceutical markets. Int J Econ Business. 2015;22(2):263–275.
   Web of Science ®Google Scholar
• European Commission. Pharmaceutical sector inquiry - final report. 2009. [cited 2013 Aug. 18. Available from: Available from: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/
   Google Scholar
• Przybyla M, Roma M Does product market competition reduce inflation? Evidence from EU countries and sectors. European Central Bank working paper, Series No. 453, 2005.
   Google Scholar
• Duso T, Herr A, Suppliet M. The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics. Health Econ. 2014;23:1036–1057.
   PubMed Web of Science ®Google Scholar
• Ganslandt M, Maskus K. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. J Health Econ. 2004;23(5):1035–1057.
   PubMed Web of Science ®Google Scholar
• Leopold C, Mantel-Teeuwisse A, Vogler S, et al. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy. 2013;112:209–216.
   PubMed Web of Science ®Google Scholar
• Lakdawalla D. Economics of the pharmaceutical industry. J Econ Lit. 2018;56(2):397–449.
   Web of Science ®Google Scholar
• Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–741.
   PubMed Web of Science ®Google Scholar
• Kostić M, Djakovic L, Šujić R, et al. Inflammatory bowel diseases (Crohn´s disease and ulcerative colitis): cost of treatment in Serbia and the implications. Appl Health Econ Health Policy. 2017;15(1):85–93.
   PubMed Web of Science ®Google Scholar
• Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
   PubMed Web of Science ®Google Scholar
• Light DW. Lexchin JR: research and development: what do we get for all that money? BMJ. 2012;345:434.
   Web of Science ®Google Scholar
• Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Sindern J, Suppliet M. Vergleichbarkeit internationaler Arzneimittelpreise - Internationale Preisreferenzierung in Deutschland durch das AMNOG. Perspektiven der Wirtschaftspolitik. 2015;16(2):164–172.
   Google Scholar